ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2026
Pretreatment geriatric nutritional risk index is associated with impaired treatment continuity and supportive care-relevant outcomes in unresectable pancreatic ductal adenocarcinoma.
Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposePatients with unresectable pancreatic ductal adenocarcinoma (PDAC) frequently experience impaired treatment continuity, and many cannot reach second-line treatment. We evaluated whether pretreatment geriatric nutritional risk index (GNRI) could identify patients at risk of impaired treatment continuity, treatment-related adverse events, and shorter survival.
methodsThis single-center retrospective study included 120 patients with unresectable PDAC who initiated first-line chemotherapy. The primary outcome was transition to second-line chemotherapy. Secondary outcomes included overall survival and treatment-related outcomes. Multivariable logistic and Cox regression analyses adjusted for age, performance status, chemotherapy regimen, distant metastasis, ascites, and carbohydrate antigen 19-9.
resultsSecond-line transition was less frequent in patients with GNRI < 92 than in those with GNRI ≥ 92 (45% vs 80%, P < 0.001). The low-GNRI group had a shorter duration of first-line chemotherapy (4.0 vs 6.9 months; P = 0.001), more frequent discontinuation within 3 months (36% vs 15%; P = 0.012), and higher frequencies of non-biliary non-hematologic adverse events and related hospitalizations. Each 1-point increase in GNRI was independently associated with second-line transition (odds ratio 1.08, 95% confidence interval 1.03-1.14) and longer overall survival (hazard ratio 0.96, 95% confidence interval 0.93-0.98).
conclusionPretreatment GNRI was associated with impaired treatment continuity, non-biliary non-hematologic adverse events and related hospitalizations, and shorter survival in unresectable PDAC. These findings support GNRI as a practical screening marker for early nutritional assessment, symptom monitoring, and multidisciplinary supportive care.
Indexed as
Identifiers
42587141What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.